NEW YORK, July 24-The Japanese pharmaceutical company Sankyo has subscribed to the nuclear receptor module of LifeSpan BioScience's drug target database, LifeSpan said yesterday.
Sankyo will use the database to help in drug target validation for diseases like diabetes, cancer and obesity. It includes immunohistochemical data and public sequence and localization data on more than 2,000 genes.
LifeSpan's database includes information on gene families of interest for drug discovery, and has eight modules. Sankyo also subscribes to the company's G-protein coupled receptor database module.
Nuclear receptors regulate gene activity related to homeostasis, development and differentiation, and have been implicated in cancer, metabolic diseases, rheumatoid arthritis and other disorders.
LifeSpan BioScience is based in Seattle.